Work

Beta-blockers in cirrhosis: Evidence-based indications and limitations

Year: 2019
Type: review
Abstract: Non-selective beta-blockers (NSBBs) are the mainstay of treatment for portal hypertension in the setting of liver cirrhosis. Randomised controlled trials demonstrated their efficacy in preventing initial variceal bleeding and subsequent rebleeding. Recent evidence indicates that NSBBs could prevent liver decompensation in patients with compensated cirrhosis. Despite solid data favouring NSBB use in cirrhosis, some studies have highlighted relevant safety issues in patients with end-stage liver disease, particularly with refractory ascites and infection. This review summarises the evidence supporting current recommendations and restrictions of NSBB use in patients with cirrhosis.
Source: JHEP Reports
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,000
OpenAlex ID: W2995510644
FWCI: 1.688
Cites: 96
Cited by: 204
Related to: 10